HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $40 Price Target

Benzinga · 10/27 15:22
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $40 price target.